West Pharmaceutical rallies after Q1 2026 earnings beat and higher full-year outlook
West Pharmaceutical Services shares jumped after the company reported first-quarter 2026 results that beat expectations and lifted its full-year 2026 outlook. Adjusted EPS was $2.13 versus an estimated ~$1.68, helping push the stock up about 13% intraday to around $312.
1) What’s driving the move
West Pharmaceutical Services (WST) is surging after releasing first-quarter 2026 results on April 23, 2026 that came in well ahead of consensus expectations and included a higher full-year 2026 outlook. The earnings surprise and upgraded forward view are the primary catalysts behind today’s roughly +12.9% move to about $312.
2) Key numbers investors are reacting to
In the quarter, West posted adjusted diluted EPS of $2.13, compared with estimates near $1.68. Investors are also focused on management’s full-year 2026 guidance update, which points to continued growth tied to higher-value product mix and demand for injectable drug components and delivery systems.
3) Capital return and positioning
West also highlighted ongoing capital return activity, including repurchasing 1.2 million shares for about $297.6 million during the quarter under its share repurchase program. With the stock reacting sharply to the earnings reset, the next debate is whether raised guidance is conservative enough given demand trends in biologics and specialty injectables.